Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Besides EGFR other tyrosine kinase receptors are currently
2021-01-19

Besides EGFR, other tyrosine kinase receptors are currently gaining attention as potential therapeutic targets. Included among these is the fibroblast growth factor receptor (FGFR) family, which is involved in the progression of a variety of cancers.7, 8, 9, 10, 11 In lung cancer, fibroblast growth
-
clemastine fumarate mg br Experimental Procedures br Acknowl
2021-01-19

Experimental Procedures Acknowledgments We thank S. Tangye and A. Swarbrick for helpful discussions and critical reading of the manuscript; K. Wood, T. Camidge, and V. Turner for technical assistance; C. Brownlee for cell sorting; the staff of the Garvan Institute Biological Testing Facility f
-
The LNX ligand of numb protein
2021-01-19

The LNX (ligand of numb protein-X) or PDZRN (PDZ and RING) family of proteins consists of five members (LNX1–LNX5), the first four of which act as E3‐ubiquitin ligases in various roles, as reviewed elsewhere [14]. LNX proteins comprise a RING domain and two to four PDZ (PSD-95, DlgA, ZO-1) domains [
-
YC 1 receptor The interface between the E ligase
2021-01-19

The interface between the E3 ligase and the E2 enzyme can vary, and ZNF451 and SP-RING ligases stabilize this interaction via noncovalent binding to a scaffold SUMO (SUMOB) on the backside of the E2 (Cappadocia et al., 2015; Eisenhardt et al., 2015; Streich & Lima, 2016). By contrast, RanBP2 does no
-
The overall shape of p iSH
2021-01-19

The overall shape of p110α/iSH2 is dramatically different from DGKB or SK1, instead of forming a homodimer, p110α/iSH2 heterodimer has a triangular shape with iSH2 laying on the top and ABD, RBD, helical and kinase domain of p110α sitting in the bottom (Fig. 2B) (Gabelli et al., 2010; Huang et al.,
-
As for antiviral activity eight out of synthesized
2021-01-19

As for antiviral activity, eight out of 23 synthesized compounds were active against influenza B virus with EC50 values in the range of 0.19–39 μM. Four of the eight influenza B hits were active against influenza A and two were also active against RSV (4 and 6, EC50 = 0.40 and 1.8 μM, respectively).
-
br Four active site residues of KSTD are fully conserved
2021-01-19

Four active site residues of Δ1-KSTD1 are fully conserved in Δ1-KSTDs from different species (Supplementary Figure S2). These residues are Tyr-119, Tyr-487, and Gly-491 from the FAD-binding domain and Tyr-318 from the catalytic domain. The structure of the Δ1-KSTD1•ADD complex revealed that the hy
-
br Use of recombinant collagen to study DDR collagen interac
2021-01-19

Use of recombinant collagen to study DDR–collagen interactions Synthetic peptides have proven highly valuable in replicating the characteristics of collagen and in defining the sites on collagen essential for binding and studying protein–collagen interactions. There are, however, disadvantages to
-
Similarly LTD concentration dependently enhanced AQP express
2021-01-18

Similarly, LTD4 concentration-dependently enhanced AQP4 expression in astrocytes (Fig. 3). The LTD4-enhanced AQP4 expression was not affected by pranlukast but inhibited by Bay u9773, a non-selective CysLT1/CysLT2 receptor antagonist [33]. Because no selective CysLT2 receptor antagonists are current
-
p kip is a member of
2021-01-18

p27kip1 is a member of the cyclin-dependent kinase (CDK) inhibitor family that acts as a potent tumor suppressor in a variety of human cancers and negatively regulates the transition of cells from the G1 to S phase of the cell cycle, protects against inflammatory injury and promotes epithelial diffe
-
Yang et al investigatedPsoralidin a coumestan
2021-01-18

Yang et al. investigatedPsoralidin 39, a coumestan derivative isolated from the seed of Psoralea corylifolia, regarding its effects on IR-induced pulmonary inflammation. Psoralidin 39 inhibited the IR-induced COX- 2 expression and PGE(2) production through regulation of PI3K/Akt and NF-κB pathway. A
-
Our results for imidacloprid were unexpected considering
2021-01-18

Our results for imidacloprid were unexpected: considering that imidacloprid (Im) is a neonicotinoid insecticide with a different mode of action (agonist of the nicotinic Cerdulatinib synthesis receptor) than OPs, we expected Es-ChE and T-ChE activity to be largely insensitive to changes in Im conce
-
A previous study reported that it is
2021-01-18

A previous study reported that it is unlikely that silkworm mounts a general type of immune response to all viruses (Liu et al., 2015). It is not clear whether there is a common pattern of host regulation for silkworm viruses. Spry is a general inhibitor of receptor tyrosine kinases (RTKs), which is
-
br Experimental Procedures Further details and an outline
2021-01-18

Experimental Procedures Further details and an outline of resources used in this work can be found in Supplemental Experimental Procedures. Introduction In response to T cell-dependent (TD) antigen stimulation, antigen-specific thymidine phosphorylase inhibitor migrate to the periphery of B
-
br Results br Discussion Drug resistance poses the greatest
2021-01-18

Results Discussion Drug resistance poses the greatest hurdle of achieving high efficacy with AADs in cancer patients. AAD-treated cancer patients often encounter intrinsic and evasive drug resistance that diminishes the therapeutic efficacy to only minor survival benefits in most cancer types.
15949 records 710/1064 page Previous Next First page 上5页 706707708709710 下5页 Last page